Current Clinical Trials
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sub-Investigator(s):
Sponsor: NSABP
Indentifier #: NCT01547741
Title: NSABP B49, A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sub-Investigator(s):
Sponsor: NSABP
Indentifier #: NCT01275677
Title: NSABP B47, A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node- Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Department: Oncology
Diagnosis: Breast
Principal Investigator: O'Brien M.D., Edward Thomas
Sub-Investigator(s):
Sponsor: NSABP
Indentifier #: NCT00769379
Title: NSABP B43, A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Department: Oncology
Diagnosis: Melanoma
Principal Investigator: O'Brien M.D., Edward Thomas
Sub-Investigator(s):
Sponsor: NCCTG
Indentifier #: NCT00976573
Title: N0879, A Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: O'Brien M.D., Edward Thomas
Sub-Investigator(s):
Sponsor: NCCTG
Indentifier #:
Title: N0392, Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lowry MD, Philip
Sub-Investigator(s):
Sponsor: Merck & Co.
Indentifier #: NCT01254630
Title: V212-011, A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy
Department: Oncology
Diagnosis: Breast- Metastatic
Principal Investigator: Lynch MD, Cynthia A.
Sub-Investigator(s):
Sponsor: Genentech
Indentifier #: NCT01615068
Title: Genentech ML 28257; An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer
Department: Oncology
Diagnosis: Cancer Control
Principal Investigator: Srivatana M.D., Panit
Sub-Investigator(s):
Sponsor: Alexion
Indentifier #: NCT01374360
Title: Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient Registry
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Lynch MD, Cynthia A.
Sub-Investigator(s):
- Cianfoni CCRP, Michelle
- Hadlock RN, CCRP, Susan
Sponsor: Tesaro
Indentifier #: NCT01500226
Title: TS-P04834, A Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy (MEC)
Department: Oncology
Diagnosis: Breast
Principal Investigator: Lynch MD, Cynthia A.
Sub-Investigator(s):
Sponsor: SCUSF
Indentifier #: NCT01009918
Title: SCUSF-0806, Phase II placebo-controlled trial of lisinopril and Coreg CR to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin)